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Serratia marcescens, a member of the Enterobacteriaceae family, is a Gram-negative bacterium responsible for a wide range of
nosocomial infections. The emergence of multidrug-resistant strains is an increasing danger to public health. To design ef-
fective means to control the dissemination of S. marcescens, an in-depth analysis of the population structure and variation
is required. Utilizing whole-genome sequencing, we characterized the population structure and variation, as well as the an-
timicrobial resistance determinants, of a systematic collection of antimicrobial-resistant S. marcescens associated with blood-
stream infections in hospitals across the United Kingdom and Ireland between 2001 and 2011. Our results show that S.
marcescens is a diverse species with a high level of genomic variation. However, the collectionwas largely composed of a limited
number of clones that emerged from this diverse background within the past few decades. We identified potential recent
transmissions of these clones, within and between hospitals, and showed that they have acquired antimicrobial resistance de-
terminants for different beta-lactams, ciprofloxacin, and tetracyclines on multiple occasions. The expansion of these multi-
drug-resistant clones suggests that the treatment of S. marcescens infections will become increasingly difficult in the future.
[Supplemental material is available for this article.]
The Gram-negative bacillus Serratia marcescens is a member of the
Enterobacteriaceae that resides in environmental soil and water
(Szewzyk et al. 1993). This species was initially considered non-
pathogenic and due to its red pigment was used by the military
to ascertain spread of bacteria in the natural environment after
deliberate release (Mahlen 2011). However over recent decades,
S. marcescens has been increasingly recognized as an important
causative agent of opportunistic nosocomial infections (Mahlen
2011). S. marcescenshas been isolated from a variety of sites includ-
ing the respiratory tract (Lancaster 1962), bloodstream (Seeyave
et al. 2006), and wounds. S. marcescens also has the potential to
cause meningitis, particularly in patients with compromised im-
mune systems (Mahlen 2011). Although existing reports suggest
community acquisition and onset for some S. marcescens infec-
tions (Laupland et al. 2008; Mahlen 2011), the number of reports
of S.marcescens infection in hospitals has seen a sharp rise. This has
led to S. marcescens being largely associated with hospital-derived
nosocomial infection. S. marcescens infections aremore often asso-
ciated with intensive care units, surgical wards, and dialysis units
(Ringrose et al. 1968; Donowitz et al. 1979; Geiseler et al. 1982;
Krishnan et al. 1991), and outbreaks of S. marcescens infection
have been observed within a single hospital (Bullock et al. 1982;
Su et al. 2003) and involving multiple hospitals within one city
(Craven et al. 1977; Hejazi et al. 2000; Naumiuk et al. 2004).
S. marcescens associated with hospital outbreaks are frequent-
ly resistant tomultiple antimicrobials. This species has intrinsic re-
sistance to several antimicrobial groups, including some classes of
beta-lactams and tetracyclines (Livermore et al. 2001; Stock et al.
2003). S. marcescens is intrinsically susceptible to other antimicro-
bial groups including quinolones and aminoglycosides, although
chromosomal or plasmid-mediated resistance has been identified
for some of these (Livermore et al. 2001; Stock et al. 2003). Like
other nosocomial pathogens, the increasing pathogenicity of S.
marcescens infections has been linkedwith the rise in the use of an-
timicrobials; however, the evidence supporting this hypothesis is
not strong for S. marcescens (Mahlen 2011).
Among the major pathogenic Enterobacteriaceae, S. marces-
cens is one of the least well-studied to date, which has beenmainly
due to the recent recognition of the species as a pathogen. Whole-
genome sequence data for S. marcescens from the environment and
clinical samples have only recently become available (Chung et al.
2013; Liu et al. 2013; Iguchi et al. 2014;Wan et al. 2015). Taken to-
gether, these indicate that the S. marcescens genome is highly dy-
namic, which reflects the diversity of environmental niches that
the bacterium occupies and the opportunistic pathogenic nature
of the organism. In addition to bacteriocin and pigment genes,
clinical isolates have been shown to harbor various beta-lactamas-
es, including ampC beta-lactamase, metallo-beta-lactamase, and
several putative multidrug efflux pumps (Chung et al. 2013; Liu
et al. 2013; Iguchi et al. 2014; Wan et al. 2015). As with other
Gram-negative nosocomial bacteria, antimicrobial resistance de-
terminants are mainly located on the accessory elements of the
S. marcescens genome (Chung et al. 2013; Liu et al. 2013; Iguchi
et al. 2014; Wan et al. 2015).
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Here, we utilized a national collection of multidrug-resistant
S. marcescens isolated from bloodstream infections to perform a
population-level study to elucidate the population structure of
the bacterium. From this, we were able to estimate time of diver-
gence of specific clones and recent nucleotide substitution rate
and identify genetic mechanisms of antimicrobial resistance.
Our results indicate that the S. marcescens population associated
with antimicrobial-resistant bloodstream infections in the
United Kingdom comprises a limited number of clades that have
undergone recent near-simultaneous expansion. Recent inter-
and intra-hospital transmissions were detected, and we demon-
strated that antimicrobial resistance determinants have been inde-
pendently acquired throughout the population.
Results
We sequenced 205 multidrug-resistant (MDR) S. marcescens iso-
lates associated with bloodstream infections in the United
Kingdom and Ireland (UK&I) that had been systematically collect-
ed by the BSAC Resistance Surveillance Project between 2001 and
2011. Since S. marcescens belongs to the Enterobacteriaceae family,
in which plasmids and mobile elements constitute an important
part of the genome, we first identified the core genome (i.e., genes
present in every isolate) and the accessory genome (i.e., genes var-
iably present between isolates) (Fig. 1A). This identified a total of
13,614 genes (the pan-genome) consisting of 3372 core genes
shared by >99% of the isolates, 342 soft core genes shared by
95%–99% of the population, 1526 shell genes shared by 15%–
95% of the population, and 8347 cloud genes shared by <15% of
the population. The numerous accessory genes underline the
diversity of the S. marcescens species and the dynamic nature of
its genome.
We then constructed a phylogenetic tree based on a core ge-
nome SNP alignment and compared this with the pattern of acces-
sory genetic elements (Fig. 1A,B). The tree revealed a highly
structured population consisting of distinct clades (Fig. 1A) with
similar branch lengths. Moreover, each clade had a unique combi-
nation of accessory genes (Fig. 1A). Comparison between a tree
constructed from the gene presence pattern in the accessory ge-
nome and the core genome tree suggested that each clade began
with a specific set of accessory genes, with little change in their
subsequent evolutionary history (Fig. 1B). The clonal structure of
the population was also evident in the distribution of pairwise
SNP distances of the core genomes (Fig. 1C). The distribution re-
vealed that genetic distance across the phylogenetic tree was large,
but that recent clonal expansion of a limited number of MDR
clades has structured the distribution of diversity (Fig. 1C).
A phylogenetic tree color coded by isolate origin showed
some evidence for geographical clustering such that closely related
isolates were found in somehospitals, although isolates from some
hospitals were distantly related and resided in different parts of the
tree (Fig. 2A). This suggests that S. marcescensMDRclades are partly
Figure 1. Pan-genome analysis of Serratia marcescens whole-genome sequences. (A) Maximum likelihood tree constructed from the core genome. On
the right, the presence (blue) and absence (white) of accessory genome elements is shown. Accessory elements located on the same contig are shown as
colored blocks along the top of the figure. (B) Comparison between the binary tree constructed from the absence and presence pattern of genes in the
accessory genome (bottom) and the maximum likelihood tree constructed from variation in the core genome (top). The lines connect identical tips of
the two trees. (C) A histogram of pairwise SNP distances between all 205 isolates. The distances are based on the core genome alignment.
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hospital (or region)-specific, but that transmission between re-
gions or hospitals has occurred. Comparing the distribution of
pairwise SNP distance with geographical distance did not show
any relationship between geographical and SNP distance for large
SNP distances (i.e., >10) (Supplemental Fig. S1). However, for close-
ly related isolates, there was a relationship between geographical
distance and SNP distance (Supplemental Fig. S1), supporting
the hypothesis that S. marcescensMDR clades have recently spread
between hospitals. To examine this, we constructed a transmission
network for isolates selected as being putatively associated with
transmission events in the past 5–10 yr (Methods) (Fig. 2B). In ad-
dition to recent transmission within hospitals, we also identified
some cases of inter-hospital transmission, mainly between geo-
graphically linked hospitals.
We then used a distance-based clustering algorithm to delin-
eate the major clades within the population and found that iso-
lates fell into nine major clades (Fig. 3A). All clades contained
isolates collected over a period of 10 yr, but these exhibit varying
degrees of geographical distribution. Specifically, although the
majority of isolates inmajor clades 1, 3, 4, 5, and 7were from a sin-
gle hospital, the other major clades contain isolates frommultiple
hospitals (Fig. 3A). This supports the hypothesis of independent
origins of largely region-specific S. marcescens major clades, with
some geographical transmission. Utilizing the variation in time
of isolation for isolates in eachmajor clade, we attempted to calcu-
late the recent nucleotide substitution rate and the age of eachma-
jor clade. The Bayesian analysis revealed that for major clades 2, 5,
6, and 8 in which the temporal signal was significant (Methods),
three major clades had a substitution rate of ∼5.8 × 10−7 SNPs/
site/year (about two SNPs per genome per year), and each major
clade had a most recent common ancestor (MRCA) between 20
and 40 yr ago (Fig. 3B,C). Clade 6 has a similar, but slightly slower
substitution rate of 2.9 × 10−7 SNPs/site/year (approximately one
per genome per year) and had an MRCA ∼80 yr ago (Fig. 3B,C).
Applying these substitution rates to the othermajor clades allowed
us to estimate MRCAs of between 10 and 80 yr ago. The recent and
near-simultaneous emergence of these major MDR clades suggests
that nosocomial MDR S. marcescens infection in the UK&I have
been largely driven by a limitednumber of dominant transmissible
MDR clones that might have been selected for by antimicrobial
use. To determine the contribution of recombination to the
intra-major clade diversity, we counted the number of recent re-
combination incidents for eachmajor clade.We found that recom-
binationwas absent inmajor clades 8 and 9 and had occurred at an
average rate between 0.01 and 0.07 events per genome per year for
the other major clades. Since these values are much smaller than
the substitution rates, we conclude that recombination has played
only a minor role in shaping the diversity within major clades.
In a previous genomic study of S. marcescens clinical strain
SM39 and insect strain Db11, plasmids pSMC1 and pSMC2 carry-
ing beta-lactam and multiple other drug resistance genes were
identified (Iguchi et al. 2014), but none of the isolates in our collec-
tion carried either of these plasmids. However, a search of the
PlasmidFinder database for plasmids revealed that some isolates
had replicons of some plasmids that were very similar to those
from other Gram-negative species including Escherichia coli and
Figure 2. Geographical distribution and transmission network analysis. (A) Isolation sites across the UK&I; (B) maximum likelihood tree with isolates col-
ored according to location. (C ) The transmission network constructed for potential transmission events. Only edges of <10 SNPs are displayed, and single-
ton nodes are not shown. Colors correspond to hospitals. Dashed circles showpotential between-hospital transmissions and the locations of those hospitals
on the map. The numbers next to edges denote pairwise SNP distance between isolates.
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Klebsiella pneumoniae, which were present in isolates scattered
throughout the tree (Supplemental Fig. S2). The plasmids identi-
fied in our collection included pJEG011 and pIGMS32 plasmids,
which have been reported previously in collections associated
with K. pneumoniae outbreaks and are known to be capable of
transferring between distantly related bacteria (Espedido et al.
2013). Moreover, the plasmids pNDM-KN, R46, and pFSEC-01,
which we found in our collection, have been shown to carry sever-
al beta-lactamase genes (Supplemental Fig. S2; Brown andWilletts
1981; Zhang et al. 2016).
We then considered antimicrobial resistance for isolates in
our collection (Supplemental Figs. S3, S4). A pairwise correlation
analysis between the MICs for different antimicrobials showed a
predictably strong correlation for three tetracyclines (tetracycline,
minocycline, and tigecycline) and between some beta-lactams, in-
cluding cefotaxime and piperacillin-tazobactam (Supplemental
Fig. S4A). It is expected that resistance determinants can confer re-
sistance tomultiple antimicrobials with similar mechanisms of ac-
tion but there are some interesting additional correlations and
anti-correlations in thematrix thatmay beworthy of further study
(Supplemental Figs. S4, S5). Based on resistance to antimicrobials
with defined clinical breakpoints (Supplemental Figs. S4B, S5B),
the collection was extensively resistant to several beta-lactams, in-
cluding amoxicillin (S:0, I:0, R:205), cefuroxime (S:3, I:0, R:202),
amoxicillin-clavulanate (S:0, I:0, R:205), cefotaxime (S:2, I:1,
R:182), piperacillin-tazobactam (S:6, I:32, R:167), and ceftazidime
(S:153, I:39, R:13). Intermediate resistance was more common to
the fluoroquinolone ciprofloxacin (S:15, I:64, R:126) and tigecy-
cline (S:132, I:57, R:13). The majority of isolates were susceptible
to imipenem (S:203, I:2, R:0) and gentamicin (S:188, I:2, R:15).
We then undertook a genetic analysis of resistance mecha-
nisms for specific drugs. Resistance to fluoroquinolones common-
ly arises as a result of alterations in the target enzymes DNA gyrase
and topoisomerase IV (Rodríguez-Martínez et al. 2011). In particu-
lar, mutations at certain sites in gyrA largely account for ciproflox-
acin resistance in Enterobacteriaceae (Dimri and Das 1990;
Deguchi et al. 1997; Weigel et al. 1998). We noted that mutations
at Ser-83 occurred in 89 isolates across the phylogenetic tree and
were strongly correlated with MIC values (Supplemental Fig. S6;
Supplemental Table S2). This mutation is the first step in selection
for elevated resistance to fluoroquinolones in E. coli (Tankovic
et al. 1994). Furthermore one isolate with an extremely high
MIC appeared to harbor the known Asp-87 resistance mutation
in gyrA (Supplemental Fig. S6; Weigel et al. 1998). In addition to
Figure 3. Temporal, geographical and phylogenetic clustering of isolates on the tree. (A) Phylogenetic treewith isolates colored according to cluster. The
nodes with bootstrap support >90 are shown in red. The pie charts show the distribution of years of isolation and the color intensity corresponds to the
temporal order, namely, the older the year of isolation the darker the color. The stacked bar plot shows the distribution of hospitals across the major clades
on the phylogenetic tree. Each color corresponds to one hospital. (B) The estimated substitution rate for the clusters with significant temporal signal. Error
bars show the 95% confidence intervals. Themutation rate is obtained by taking the average of three independent BEAST runs. (C) The estimated age of the
MRCA for each cluster. Error bars correspond to 95% confidence interval for clusters shown in B. For the clusters without significant temporal signals, i.e.,
clusters 1, 3, 4, 7, and 9, we calculated the mean root age by using the mean substitution rate for clusters 2, 5, 6, and 8. For error bars, we considered the
substitution rates obtained for maximum and minimum of 95% confidence intervals for clusters 2, 5, 6, and 8.
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these chromosomal mutations, the acquisition of a variant in the
theta subunit of DNA polymerase III, seemingly inserted within
the chromosome, by some subclades is strongly associated with el-
evated MIC values for ciprofloxacin (Supplemental Fig. S6).
Although its function is not fully elucidated, this subunit is
thought to be implicated in the stabilization of the epsilon subunit
of DNA Polymerase III, which is involved in DNA proofreading, es-
pecially under extreme conditions (Taft-Benz and Schaaper 2004).
Further analysis is required to elucidate the connection between
ciprofloxacin and the theta subunit.
Resistance to aminoglycosides is mediated through the ac-
tion of aminoglycoside modifying enzymes, i.e., acyltransferases,
adenylyltransferase, or phosphotransferases. All isolates harbored
acyltransferase aac(6′)-Ic, a well-known chromosomally encoded
resistance gene (Champion et al. 1988), and some isolates carry
aadA, although these genes did not appear to affect susceptibility
of the population to gentamicin. However, reduced susceptibility
to gentamicin occurred independently in some subclades of the
major clades across the tree and could be attributed to the presence
of one of aminoglycoside phosphotransferase aph(3′), acetyltrans-
ferase aac, or adenylyltransferase aadb (Supplemental Fig. S6).
These genes seem to be located on wide host range plasmids orig-
inally identified in K. pneumoniae: The aadB gene is located on
pMU407 shown in Supplemental Figure S2. The aac(3)-I gene oc-
curs in the context of an IncFII group conjugative plasmid, previ-
ously reported as a multidrug resistance gene carrier (Rodríguez
et al. 2010), and the aph(3′) and aac(3)-II genes are situated on var-
ious K. pneumoniae multidrug resistance plasmids.
S. marcescens collections have been reported to be uniformly
resistant to tetracycline (Livermore et al. 2001; Stock et al. 2003).
Despite this, we found a significant variation inMIC values for tet-
racyclines for our isolates (Supplemental Fig. S5A,B). Increased re-
sistance to tetracycline occurred independently in four subclades
across the phylogenetic tree and was linked with the presence of
efflux pumps tetA5 and tetA3, both of which have been reported
as resistance determinants (Supplemental Fig. S6; Bollmann et al.
1989). The tetA5 gene also accounted for the elevated resistance
to minocycline in 16 samples and appears to be inserted within
the chromosome (Table 1). The tetA3 efflux gene, however, was
found in the context of the pIGT15 plasmid, which originates
from a clinical Escherichia coli isolate (Adamczuk et al. 2015). The
presence of tetracycline transporter tet41 in some isolates across
the tree did not affect the susceptibility to tetracylines.
Among the beta-lactam antimicrobials that we studied
here, resistance in S. marcescens has been reported previously to
ampicillin, amoxicillin, amoxicillin-clavulanate, and cefuroxime
(Livermore et al. 2001; Stock et al. 2003). This is largely attributed
to the plasmid-mediated extended-spectrum beta-lactamases
(ESBLs) and the chromosomal ampC beta-lactamase, which can
be induced by cefoxitin, imipenem, and amoxicillin as well as by
somecephalosporins includingceftazidime, cefotaxime, andcefur-
oxime (Hanson and Sanders 1999; Naumiuk et al. 2004). Although
every isolate in our collection contained ampC, only two samples
were phenotypically detected as ESBL positive. Although one of
the ESBL-positive isolates appears to carry a copy of bla-SHV, locat-
ed in the context of a broad host range Klebsiella pneumoniae plas-
mid (pKEC-dc3), we did not identify any ESBL gene in the other
isolate. The rarity of ESBLs indicates that resistance to cephalospo-
rins and penicillin is predominantly mediated by chromosomal
genes. Despite this, variation in the MIC values for some cephalo-
sporins suggests that part of thepopulationhas acquired additional
resistance mechanisms. In Table 1, we report some potential ele-
ments strongly associated with elevatedMICs. Among beta-lactam
antimicrobials, the population is extensively susceptible only to
imipenem (Supplemental Figs. S4, S5B), which can be explained
by the lackofwell-knowncarbapenamases suchas theKPCenzyme
Table 1. Antimicrobial resistance determinants identified by mining a resistance gene database and potential determinants that strongly cor-
relate with MIC
Antimicrobial
class
Antimicrobial
subclass Antimicrobiala Resistance determinant Frequency
Association
valueb Methodc
Beta-lactam Penicillin amx Beta-lactamase TEM precursor 16/205 5.41 1
Beta-lactam Cephalosporin cxm Multidrug resistance mexA precursor 202/205 10.53 1
Beta-lactam Cephalosporin ctx ampC beta-lactamase precursor 1/205 9.49 1
Beta-lactam Carbapenem imp ampC beta-lactamase precursor 1/205 29.21 1
Fluoroquinolone Ciprofloxacin cip Ser-83 gyrA DNA gyrase subunit A 89/205 6.53 3
Asp-87 gyrA DNA gyrase subunit A 1/205 42.33 3
Asn-26 rssB response regulator of RpoS 3/205 9.85 3
SMWW4_v1c19250 NA 5.39 2
DNA modification protein
DNA polymerase III subunit theta 18/205 5.58 1
Aminoglycoside Gentamicin gen aph(3′)-I phosphotransferase 3/205 NA 4
aac(3)-Ia acetyltransferase 8/205 NA 4
aac(3)-Ic acetyltransferase 1/205 NA 4
aac(3)-II acetyltransferase 3/205 NA 4
aadb adenyltransferase 3/205 NA 4
Tetracycline Tetracycline tet tetA_5 metal-tetracycline/H antiporter 16/205 6.72 1
tetA_3 tetracycline resistance protein 8/205 53.30 1
tetR tetracycline repressor protein
class H
15/205 26.29 1
ompC_1 porin ompk36 12/205 26.29 1
Tetracyline Minocycline min tetA_5 metal-tetracycline/H antiporter 16/205 18.63 1
a(amx) amoxicillin; (cxm) cefuroxime; (ctx) cefotaxime; (imp) imipenem; (cip) ciprofloxacin; (gen) gentamicin; (min) minocycline; and (tet) tetracy-
cline.
bAssociation values are expressed as −log10 P-values format and reported only for the genes found by the regression model.
cThe method used to find the resistance determinants: (1) regression model on the accessory genes; (2) regression model on nonsynonymous SNP
counts; (3) regression model on individual SNP presence; and (4) srst2.
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(Cai et al. 2008) and the metallo-beta-lactamase imp enzyme
(Osano et al. 1994). The isolate with a high MIC for imipenem ap-
peared toharboran extra copyofampC, suggesting theoverproduc-
tion of AmpC was responsible for imipenem resistance in this
isolate, as previously reported (Jacoby 2009; Lister et al. 2009).
Table 1 presents some of the putative antimicrobial resistance de-
terminants that exhibit a strong association with MICs, and a full
list of gene/SNP hits, strongly associated with resistance, is provid-
ed as Supplemental Tables S2–S4.
Discussion
We have described an in-depth analysis of a collection of MDR
S. marcescens from bloodstream infections in the UK&I, in which
we elucidated the population structure and dynamics, as well as
antimicrobial resistance determinants. S. marcescens was previous-
ly believed to be a nonpathogenic environmental species but has
been recognized as an increasingly important opportunistic path-
ogen over the past few decades (Mahlen 2011). The large accessory
genome and genomic flexibility is likely to be important for its
ability to act as an opportunistic pathogen (Aujoulat et al. 2012).
Our results revealed that theMDR S.marcescenspopulation re-
sponsible for bloodstream infections in UK&I hospitals has a
strongly clonal structure, with a limited number of clones having
emerged within the last few decades. Utilizing the fine resolution
of whole-genome sequencing, we were able to identify potential
transmissions of these MDR clones between and within hospitals.
In spite of several cases of within-hospital transmissions, we found
that pathogens within some hospitals had very different origins,
implying either that some patients acquired the infection outside
hospital or that inter-hospital transmission had taken place. More
detailed tracking of all S. marcescens infections within a hospital or
healthcare system would shed more light on the structure of the
underlying transmission network.
The rapid increase of nosocomial S. marcescens infections and
the rise in the use of antimicrobials indicates that recent antimi-
crobial therapy might have initiated the emergence or accelerated
the spread ofMDR S. marcescens clones. This hypothesis appears to
hold to some extent for our isolates as the increasedMIC values oc-
cur uniformly across the phylogenetic tree, and identical antimi-
crobial resistant determinants at both SNP and gene levels have
been acquired multiple times across the tree. This is further sup-
ported by the parallel emergence of resistance variants through
the acquisition of antimicrobial resistance genes or mutations, as
shown in Supplemental Figure S5. Furthermore the pattern of ac-
quisition of resistance determinants across the phylogenetic tree
appeared to be different for various genes. In some cases (e.g.,
tetA-5), all isolates within a major clade acquired the resistance
genes, although in many cases (e.g., accA and aadB genes), several
subclades of major clades have gained the gene. The latter mode of
resistance acquisition by subclades ofmajor clades suggests that ei-
ther the subclades still undergo changes in response to antimicro-
bial treatment or other evolutionary forces contribute to variation
in resistance levels.
The current therapy for Serratia infections includes an amino-
glycoside plus a beta-lactam and/or a carbapenem, since the single
use of a beta-lactam can select for resistant strains. Our findings of
correlated resistance demonstrate that the concurrent application
of most beta-lactams may be ineffective and only gentamicin,
imipenem, and to a lesser extent, tigecycline, appear to still offer
effective treatment (Hope et al. 2006; Harris and Ferguson 2012).
Gentamicin was commonly used during the 1970s, and as a result,
resistance quickly arose at that time (Yu et al. 1979). However, the
increasing use of other antimicrobials, such as ciprofloxacin and
cephalosporins, led to a reduction in the use of gentamicin. The
uniform lack of resistance in the clones identified here suggests
that the earlier gentamicin-resistant S. marcescens may have be-
longed to a clone (or clones) that has subsequently been lost
from the population by competition with extant clones, although
it is possible that the current clones may once have been gentami-
cin resistant. The reuse of gentamicin in clinical practice can how-
ever accelerate the spread of the few antimicrobial resistance
determinants we identified, and this could result in outbreaks of
aminoglycoside resistant S.marcescens as has been observed recent-
ly (Mlynarczyk et al. 2007; Ivanova et al. 2008).
Compared to other major nosocomial pathogens, less atten-
tion has been paid to S. marcescens infections due to its lower
prevalence. Moreover, no genetic typing method is available for
S. marcescens. Using whole-genome sequencing has allowed us to
demonstrate that most MDR S. marcescens in UK&I hospitals be-
longed to a limited number of clones of recent origin, reminiscent
of the much better studied clonal structure of methicillin resistant
Staphylococcus aureus (MRSA) (Reuter et al. 2016).Onequestion that
is not answered by this study is whether antimicrobial-susceptible
S.marcescens infections are also causedby recent clones, orwhether
any representativeof thebroader species is capableof opportunistic
infection.A global understandingof the evolutionof antimicrobial
resistance and dissemination of nosocomial S. marcescens could be
attained using a broader collection from various sources, includ-
ing a wide geographical distribution, different infection sources
(e.g., wounds or urinary tract infections), and community/nosoco-
mial origin, as has been done for other Enterobacteriaceae (Holt
et al. 2015).
Methods
Isolates and antimicrobial susceptibility testing
The study was approved by the National Research Ethics Service
(ref: 12/EE/0439) and the CUH Research and Development
(R&D) Department. A national collection of 205 S. marcescens
isolates was provided by the British Society for Antimicrobial
Chemotherapy (BSAC) Resistance Surveillance project (http://
www.bsacsurv.org) and consisted of isolates submitted to a bacter-
aemia surveillance program between 2001 and 2011 by 31 hospi-
tals across the United Kingdom and Ireland. Multidrug resistance
(MDR) was defined as acquired nonsusceptibility to at least one
agent in three or more antimicrobial categories (Magiorakos et al.
2012), and isolates in this collection were selected based on the
presence of phenotypic resistance to at least one antimicrobial in
three of the following groups: penicillins, carbapenems, cephalos-
psorins, tetracyclines, aminoglycoside, and fluoroquinolones. A
list of isolates is provided in Supplemental Table S1. Theminimum
inhibitory concentration (MIC) for each antimicrobial agent was
determined using the BSAC agar dilution method. Antimicrobials
included beta-lactams (penicillin: amoxicillin; cephalosporins:
cefuroxime, cefoxitin, cefotaxime, ceftazidime, and piperacillin-
tazobactam and amoxicillin-clavulanic acid), tetracyclines (mino-
cycline, tetracycline, and tigecycline), aminoglycosides (gentami-
cin), and fluoroquinolones (ciprofloxacin). We compared the
distribution of MIC values of our samples with those from the
European Committee on Antimicrobial Susceptibility Testing
(EUCAST). These, along with the clinical susceptibility break-
points used in our study were downloaded from the EUCAST web-
site (http://www.eucast.org) on May 1, 2016.
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Sequencing, pan-genome analysis and phylogeny
DNA was extracted using QIAxtractor (Qiagen), according to the
manufacturer’s instructions. Library preparation was conducted
according to the Illuminaprotocol, and sequencingwas performed
on an Illumina HiSeq2000 with a read length of 2 × 100 bp.
Ninety-six samples were multiplexed per lane to give an average
depth of coverage of 79-fold. The raw sequences and assembled
data have been deposited in the ENA under the accession numbers
shown in Supplemental Table S1. Paired-end sequence reads were
assembled using an in-house assembly and improvement pipeline
based on Velvet (Zerbino and Birney 2008) and annotated with
Prokka, which takes fragmented de novo assemblies (Seemann
2014). To identify core and accessory genes, we used the annotated
assemblies produced by Prokka as input to Roary, a tool that rapid-
ly builds large-scale pan-genomes (Page et al. 2015). Isolates were
then clustered based on the presence of various genes in the acces-
sory genome, with the contribution of isolates to the graph
weighted by cluster size. The maximum likelihood phylogenetic
tree from the core genome was built with RAxML using a general
time reversible (GTR) evolutionary model and a gamma correction
for among site rate variation (Stamatakis 2014). We conducted
one hundred bootstrap replicates to quantify the significance of
nodes in the maximum likelihood tree. We used in-house tools,
Microreact (http://microreact.org) and Dendroscope (Huson and
Scornavacca 2012) to visualize the results.
Recombination analysis
We used Gubbins to identify regions of the genomes that had un-
dergone recent homologous recombination. The tool detects re-
combination based on the elevated SNP density, which identifies
homologous recombination from within or outside the tree
(Croucher et al. 2015). For nucleotide substitution rate estimation,
we constructed a maximum likelihood phylogeny from the multi-
ple alignment file that Gubbins produces after excluding the re-
combinant regions.
Transmission analysis and cluster analysis
We constructed the network of potential recent transmission
events using the R package adegene, which maximizes the likeli-
hood of the network constructed from pairwise SNP distances be-
tween samples (Jombart and Ahmed 2011; Jombart et al. 2011).
We excluded edges corresponding to more than 10 SNPs, which
given the estimate of the recent substitution rate of the core ge-
nome of S. marcescens, corresponds to SNPs accumulated over ∼5
to 10 yr (Results). We identified clusters of samples within our col-
lection using an unsupervised clustering algorithm in the adegene
package. The tool takes the pairwise SNP distancematrix and a SNP
cut-off and generates the clusters. Thismeans that for larger cut-off
values, fewer clusters are produced. To find the best cut-off for clus-
tering, we screened the SNP cut-off values from 0, which gives 205
clusters, to very large values, which give one cluster. After exclud-
ing five outliers that are too far from the rest of the samples, we
identified 26 groups, which remained robust against changing
cut-off values for 102,322 SNPs.We considered only the nine clus-
ters with more than five members for substitution rate analysis.
These nine clusters include 178 isolates in total.
Phylogenetic analysis and mutation rate calculation
To estimate recent nucleotide substitution rate, we constructed
multiple alignments for each cluster after eliminating recombined
regions and then reconstructed themaximum likelihood phyloge-
netic tree. We used this to plot root-to-tip distance versus year of
isolation for each sample. To evaluate the significance of the tem-
poral signal in each cluster, we performed 10,000 bootstraps with
randomized years to obtain a distribution for R-squared values and
compared the real R-squared values with the distribution.We then
estimated the substitution rate and the age of the root node with
BEAST v1.7 (Drummond and Rambaut 2007) for the clusters in
which temporal signals within the data were found to be signifi-
cant (90% confidence interval).
We examined various models including a strict molecular
clock, a GTR model with a gamma correction for among site vari-
ation, and relaxed exponential model with constant population
model (the models yielded similar results). For each parameter
set, three independent chains were conducted for 100million gen-
erations with sampling every 10 generations. Subsequently, con-
vergence was assessed for each model by checking that ESS
values were greater than 200 for key parameters. We also checked
that independent runs had converged on similar values. A burn-in
of 10million states was left out fromeach of the three independent
runs of this model. We then combined the results from those runs
with the logcombiner program from the BEAST package. We took
the age of the root as the height of the root of theMaximumClade
Credibility (MCC) tree reconstructed by combining trees using the
tree annotator program from the BEAST package.
Regression analysis and identification of antimicrobial resistance
determinants
To identify antibiotic resistance genes in the isolates, we used srst2
(Inouye et al. 2014) to map short reads to known resistance genes
in the Resfinder data set of the srst2 package (coverage cut-off
90%). As a complement to this approach, we utilized the MIC val-
ues to identify putative antibiotic resistance determinants that are
associated with elevatedMIC values. To this end, we usedmultiple
regression approaches, i.e., identifying genes in which the number
of nonsynonymous SNPs strongly correlates with resistance level;
identifying genes in the accessory genome, the presence of which
strongly correlates with resistance level; and finally identifying
SNPs that strongly correlate with resistance levels. By doing so,
we aimed to find not only already well-known resistance genes
but also any putative resistance determinant that might be impli-
cated in increasing resistance to a particular antimicrobial.
We directly used MIC values, instead of categorical resistant/
susceptible status, as the predictor parameter in the regression
analyses for two reasons: First, MIC values allowed us to address
a more general question of what elements increase resistance lev-
els. Second, the higher variationwithinMICvalues than in the cat-
egorical resistance status provides the regression model with more
information to yield more significant results (the variance of MIC
values for some antimicrobials was not sufficiently large for regres-
sion analysis).
We performed regression analysis to single out potential resis-
tance genes by taking the presence and absence of genes in the ac-
cessory genome as the predictor and MIC values as the dependent
parameter. We then obtained the list of hits, i.e., genes with asso-
ciation value (P-value) <10−5, and excluded genes, such as phage
genes, that were highly unlikely to play a role in resistance from
the list of hits. Subsequently, we screened the list to find putative
resistance genes. Although this approach helped us to find some
potential resistance genes for some antimicrobials, we did not
identify any gene for a few antimicrobials. This might be due to
nongenetic or complex genetic effects, not studied here, on varia-
tion in MIC values, or the signal not being sufficiently strong for a
significant result to be obtained with the cut-off used.
To conduct the SNP based association studies, we first
mapped the short reads against the reference genome S. marcescens
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WW4 (accessionnumber: CP003959) using SMALT v0.7.4 (https://
www.sanger.ac.uk/resources/software/smalt/). SNPs were then an-
notated using a combination of SAMtools mplieup (Li et al. 2009)
andBCFtools as detailed inHarris et al. (2010). The SNPassociation
regression model identified SNPs that were strongly correlated
with MIC values. In this analysis, sites with >10% unknown
SNPs were excluded. In our second SNP-based analysis, we at-
tempted to find genes with a strong association between their var-
iation pattern and MIC. To this end, we computed the correlation
between the number of nonsynonymous mutations and MIC for
each gene in our database. As with the accessory gene-based mod-
el, we set a stringent P-value cut-off of <10−5 to obtain a list of hits.
We used the SNP association method primarily for ciprofloxacin,
resistance against which is primarily caused by mutations in chro-
mosomal genes. In all the aforementioned regression models, we
corrected and accounted for population structure by incorporating
the clusters previously identified on the phylogenetic tree into the
model.
Data access
The sequence data for the isolates from this study have been
submitted to the European Nucleotide Archive (ENA; http://
www.ebi.ac.uk/ena) under accession numbers PRJEB5065 and
ERP004424. The sequences of the genes in the pan-genome have
been submitted to the Mendeley database (https://data.mendeley.
com/) (Moradigaravand 2016).
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